MARKET

CTMX

CTMX

Cytomx Therapeutics Inc
NASDAQ
1.730
+0.050
+2.98%
After Hours: 1.680 -0.05 -2.89% 19:27 06/02 EDT
OPEN
1.690
PREV CLOSE
1.680
HIGH
1.730
LOW
1.680
VOLUME
156.65K
TURNOVER
0
52 WEEK HIGH
3.020
52 WEEK LOW
1.170
MARKET CAP
114.77M
P/E (TTM)
-1.4475
1D
5D
1M
3M
1Y
5Y
Cytomx Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 05/24 00:26
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now
NASDAQ · 05/19 15:09
CytomX Therapeutics (CTMX) Receives a Hold from H.C. Wainwright
TipRanks · 05/10 11:55
CytomX Therapeutics (CTMX) Receives a Hold from Mizuho Securities
TipRanks · 05/10 03:45
BRIEF-Cytomx Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Reuters · 05/09 22:07
CytomX GAAP EPS of -$0.05 beats by $0.06, revenue of $23.5M beats by $3.59M
Seeking Alpha · 05/09 21:58
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/09 21:35
CytomX Therapeutics: Q1 Earnings Insights
Benzinga · 05/09 20:40
More
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company's product candidates include the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX2009, targeting CD166) and CX-2029, targeting CD71, and the Probody immune checkpoint inhibitors pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4). It also has two preclinical agents in investigational new drug (IND)-enabling studies - a conditionally activated ADC targeting EpCAM/Trop-1 (CX-2043) and a conditionally activated T-cell engaging bispecific antibody targeting EGFR and CD3 (CX-904).

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.